Nanocapsules Comprised of Purified Protein: Construction and Applications in Vaccine Research
Authors:
- Ivana SkakicISIvana Skakic
- Aya C. TakiATAya C. Taki
- Jasmine E. FrancisJFJasmine E. Francis
- Chaitali DekiwadiaCDChaitali Dekiwadia
- Thi Thu Hao VanTVThi Thu Hao Van
- Carina C. D. JoeCJCarina C. D. Joe
- Tram PhanTPTram Phan
- George LovreczGLGeorge Lovrecz
- Paul R. GorryPGPaul R. Gorry
- Paul A. RamslandPRPaul A. Ramsland
- Anna K. WalduckAnna K. Walduck
- Peter M. SmookerPSPeter M. Smooker
Open Access
Abstract
Nanoparticles show great promise as a platform for developing vaccines for the prevention of infectious disease. We have been investigating a method whereby nanocapsules can be formulated from protein, such that the final capsules contain only the cross-linked protein itself. Such nanocapsules are made using a silica templating system and can be customised in terms of size and porosity. Here we compare the construction and characteristics of nanocapsules from four different proteins: one a model protein (ovalbumin) and three from infectious disease pathogens, namely the influenza virus, Helicobacter pylori and HIV. Two of the nanocapsules were assessed further. We confirm that nanocapsules constructed from the urease A subunit of H. pylori can reduce subsequent infection in a vaccinated mouse model. Further, we show that capsules constructed from the HIV gp120 protein can be taken up by dendritic cells in tissue culture and can be recognised by antibodies raised against the virus. These results point to the utility of this method in constructing protein-only nanocapsules from proteins of varying sizes and isoelectric points.Keywords
Funding Information
- CASS Medicine and Science (SM/14/5403/DSA:DR, CDF17137)
- RMIT Capability Development Fund (SM/14/5403/DSA:DR, CDF17137)
This publication has 29 references indexed in Scilit:
- Lipid Nanoparticle-Based Delivery System─A Competing Place for mRNA VaccinesACS Omega, 2024
- Recent advances in nano- and micro-scale carrier systems for controlled delivery of vaccinesBiomaterials, 2023
- Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in IndiaThe Lancet, 2022
- Vaccine delivery systems toward lymph nodesAdvanced Drug Delivery Reviews, 2021
- Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal modelsVaccine, 2021
- Protein-only nanocapsules induce cross-presentation in dendritic cells, demonstrating potential as an antigen delivery systemNanomedicine: Nanotechnology, Biology and Medicine, 2020
- Decoupling the Effects of the Size, Wall Thickness, and Porosity of Curcumin-Loaded Chitosan Nanocapsules on Their Anticancer Efficacy: Size Is the WinnerLangmuir, 2012
- Local recall responses in the stomach involving reduced regulation and expanded help mediate vaccine‐induced protection against Helicobacter pylori in miceEuropean Journal of Immunology, 2010
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strainGastroenterology, 1997